Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

• Status: Completed
• Trial end date: 2018-01-16
• Target enrollment: 0
• Participant gender: All

Summary

This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Males and female subjects;

• Body Mass Index 30-40 kg/m2;

Exclusion Criteria:

• Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)